Skip to main content
SpringerLink
Log in

Contraception in Chronic Kidney Disease and Renal Transplantation

  • Chapter
  • First Online:
Obstetric and Gynecologic Nephrology

Abstract

Due to the increase in the chronic kidney disease and transplant population, contraception counseling is essential in preventing unplanned pregnancies during the pre- and post-transplant period. Unintended pregnancy can have devastating effects on both mother and fetus. The physician must work with the patient to find the best method of contraception, taking into account patient preference as well as medical comorbidities. The LNG-IUS is an ideal option for the CKD and transplant patient as it is a first-line method, will help decrease monthly blood loss, and is easily reversible. In addition to the IUD, the ENG-implant is a good progestin-only method due to its high efficacy and ease of use. Individual bleeding patterns may vary but can be treated. Combined hormonal methods may be appropriate on a case-by-case basis, but have higher failure rates. If pregnancy occurs and termination is desired, the decision for an inpatient versus outpatient procedure will depend on the individual’s clinical status. Consultation with a family planning specialist is advised. Most women will not be candidates for medical termination.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med. 2016;374(9):843–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Watnick S, Rueda J. Reproduction and contraception after kidney transplantation. Curr Opin Obstet Gynecol. 2008;20(3):308–12.

    Article  PubMed  Google Scholar 

  3. Sachdeva M, et al. Pregnancy outcomes in women on hemodialysis: a national survey. Clin Kidney J. 2017;10(2):276–81.

    PubMed  PubMed Central  Google Scholar 

  4. Deshpande NA, et al. Pregnancy outcomes in kidney transplant recipients: a systematic review and meta-analysis. Am J Transplant. 2011;11(11):2388–404.

    Article  CAS  PubMed  Google Scholar 

  5. McKay DB, et al. Reproduction and transplantation: report on the AST consensus conference on reproductive issues and transplantation. Am J Transplant. 2005;5(7):1592–9.

    Article  PubMed  Google Scholar 

  6. Curtis KM, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1–103.

    Article  PubMed  Google Scholar 

  7. Curtis KM, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(4):1–66.

    Article  PubMed  Google Scholar 

  8. Stehman-Breen C, et al. Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis. Kidney Int. 2003;64(1):290–4.

    Article  CAS  PubMed  Google Scholar 

  9. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Contraception. 1998;57(5):315–24.

    Article  Google Scholar 

  10. Heinemann LA, et al. Oral progestogen-only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women. Eur J Contracept Reprod Health Care. 1999;4(2):67–73.

    Article  CAS  PubMed  Google Scholar 

  11. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet. 1999;354(9190):1610–1.

    Article  CAS  PubMed  Google Scholar 

  12. Diedrich JT, et al. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol. 2015;212(1):50 e1–8.

    Article  Google Scholar 

  13. Pakarinen P, Luukkainen T. Treatment of menorrhagia with an LNG-IUS. Contraception. 2007;75(6 Suppl):S118–22.

    Article  CAS  PubMed  Google Scholar 

  14. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990;97(8):690–4.

    Article  CAS  PubMed  Google Scholar 

  15. Stefanski A, et al. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int. 1996;50(4):1321–6.

    Article  CAS  PubMed  Google Scholar 

  16. Benagiano GDE, Goldzieher JW, Gray R, Apelo R, Bergstein N, JC DS, Devi PK, Kesseru E, Koetsawang S, Ojo OA, Gupta AN, Pretnar A, Toppozada HK. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate: 2. Bleeding patterns and side effects. Contraception. 1978;17(5):395–406.

    Article  Google Scholar 

  17. Nilsson CG, et al. Two years’ experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study. Fertil Steril. 1983;39(2):187–92.

    Article  CAS  PubMed  Google Scholar 

  18. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception. 1994;50(6 Suppl 1):S1–195.

    CAS  PubMed  Google Scholar 

  19. Mansour D, et al. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008;13(Suppl 1):13–28.

    Article  CAS  PubMed  Google Scholar 

  20. Laifer SA, et al. Pregnancy and liver transplantation. Obstet Gynecol. 1990;76(6):1083–8.

    CAS  PubMed  Google Scholar 

  21. Mastrobattista JM, Gomez-Lobo V. Society for Maternal Fetal Medicine, Pregnancy after solid organ transplantation. Obstet Gynecol. 2008;112(4):919–32.

    Article  Google Scholar 

  22. Sibanda N, et al. Pregnancy after organ transplantation: a report from the UK transplant pregnancy registry. Transplantation. 2007;83(10):1301–7.

    Article  PubMed  Google Scholar 

  23. Murray JE, et al. Successful pregnancies after human renal transplantation. N Engl J Med. 1963;269:341–3.

    Article  CAS  PubMed  Google Scholar 

  24. Coscia LA, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2010:65–85.

    Google Scholar 

  25. Armenti VT, et al. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation. Clin Transpl. 2006:57–70.

    Google Scholar 

  26. Rose C, et al. Timing of pregnancy after kidney transplantation and risk of allograft failure. Am J Transplant. 2016;16(8):2360–7.

    Article  CAS  PubMed  Google Scholar 

  27. French VA, et al. Contraception and fertility awareness among women with solid organ transplants. Obstet Gynecol. 2013;122(4):809–14.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Rafie S, et al. Contraceptive use in female recipients of a solid-organ transplant. Prog Transplant. 2014;24(4):344–8.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hatcher RA, Trussell J, Nelson A, Cates W, Kowal D, Policar M. Contraceptive technology. 20th ed. Atlanta: Ardent Media; 2011.

    Google Scholar 

  30. Winner B, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.

    Article  CAS  PubMed  Google Scholar 

  31. Diedrich JT, et al. Three-year continuation of reversible contraception. Am J Obstet Gynecol. 2015;213(5):662 e1–8.

    Article  Google Scholar 

  32. Hricik DE. Transplant immunology and immunosuppression: core curriculum 2015. Am J Kidney Dis. 2015;65(6):956–66.

    Article  PubMed  Google Scholar 

  33. Hart A, et al. OPTN/SRTR 2016 annual data report: kidney. Am J Transplant. 2018;18(Suppl 1):18–113.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Ramhendar T, Byrne P. Use of the levonorgestrel-releasing intrauterine system in renal transplant recipients: a retrospective case review. Contraception. 2012;86(3):288–9.

    Article  CAS  PubMed  Google Scholar 

  35. Fong YF, Singh K. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient. Contraception. 1999;60(1):51–3.

    Article  CAS  PubMed  Google Scholar 

  36. Bahamondes MV, et al. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception. 2011;84(5):e11–6.

    Article  CAS  PubMed  Google Scholar 

  37. Tepper NK, et al. Safety of intrauterine devices among women with HIV: a systematic review. Contraception. 2016;94(6):713–24.

    Article  PubMed  Google Scholar 

  38. Kim CR, et al. Immunologic evaluation of the endometrium with a levonorgestrel intrauterine device in solid organ transplant women and healthy controls. Contraception. 2016;94(5):534–40.

    Article  CAS  PubMed  Google Scholar 

  39. Juliato CRT, Stahlschmidt P, Fernandes A, Monteiro I, Bahamondes L. A case series on the use of levonorgestrel 52 mg intrauterine system after organ transplant. Contraception. 2018;98(3):252–4.

    Article  CAS  PubMed  Google Scholar 

  40. Zerner J, et al. Intrauterine contraceptive device failures in renal transplant patients. J Reprod Med. 1981;26(2):99–102.

    CAS  PubMed  Google Scholar 

  41. Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception. 2007;75(6 Suppl):S16–30.

    Article  CAS  PubMed  Google Scholar 

  42. Allen RH, Cwiak CA. Contraception for the medically challenging patient. New York, NY: Springer; 2014.

    Google Scholar 

  43. Roger T, et al. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol. 2005;35(12):3405–13.

    Article  CAS  PubMed  Google Scholar 

  44. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years’ comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol. 1991;77(2):261–4.

    Article  CAS  PubMed  Google Scholar 

  45. Farley TM, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339(8796):785–8.

    Article  CAS  PubMed  Google Scholar 

  46. Hubacher D, et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345(8):561–7.

    Article  CAS  PubMed  Google Scholar 

  47. Long-acting reversible contraception: implants and intrauterine devices. Practice Bulletin No. 186. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2017;130e251–69.

    Google Scholar 

  48. McNicholas C, et al. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol. 2017;216(6):586 e1–6.

    Article  CAS  Google Scholar 

  49. Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception. 2014;89(6):495–503.

    Article  PubMed  Google Scholar 

  50. Mansour D, et al. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception. 2011;83(3):202–10.

    Article  CAS  PubMed  Google Scholar 

  51. Schwallie PC, Assenzo JR. Contraceptive use – efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril. 1973;24(5):331–9.

    Article  CAS  PubMed  Google Scholar 

  52. Clark MK, et al. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86(5):1466–74.

    Article  CAS  PubMed  Google Scholar 

  53. Canalis E, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319–28.

    Article  CAS  PubMed  Google Scholar 

  54. Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97(1):14–21.

    Article  PubMed  Google Scholar 

  55. Pietrzak B, et al. Combined oral contraception in women after renal transplantation. Neuro Endocrinol Lett. 2006;27(5):679–82.

    CAS  PubMed  Google Scholar 

  56. Paternoster DM, et al. The contraceptive vaginal ring in women with renal and liver transplantation: analysis of preliminary results. Transplant Proc. 2010;42(4):1162–5.

    Article  CAS  PubMed  Google Scholar 

  57. Jabiry-Zieniewicz Z, et al. Low-dose hormonal contraception after liver transplantation. Transplant Proc. 2007;39(5):1530–2.

    Article  CAS  PubMed  Google Scholar 

  58. Cleland K, et al. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod. 2012;27(7):1994–2000.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Glasier AF, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375(9714):555–62.

    Article  CAS  PubMed  Google Scholar 

  60. Moreau C, Trussell J. Results from pooled phase III studies of ulipristal acetate for emergency contraception. Contraception. 2012;86(6):673–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Glasier A, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84(4):363–7.

    Article  CAS  PubMed  Google Scholar 

  62. Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG, Creinin, MD. Management of Unintended and Abnormal Pregnancy: Comprehensive Abortion Care. Hoboken, NJ: John Wiley and Sons, 2009.

    Google Scholar 

  63. Creinin MD, Grossman DA. Medical management of first-trimester abortion. Contraception. 2014;89(3):148–61.

    Google Scholar 

  64. Diagnosis of abnormal uterine bleeding in reproductive-aged women. Practice Bulletin No. 128. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2012;120:197–206.

    Google Scholar 

  65. Munro MG, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3–13.

    Article  PubMed  Google Scholar 

  66. Fraser IS, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril. 2007;87(3):466–76.

    Article  PubMed  Google Scholar 

  67. James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia. 2005;11(4):295–307.

    Article  CAS  PubMed  Google Scholar 

  68. Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem. 1999;45(7):942–56.

    CAS  PubMed  Google Scholar 

  69. Vladutiu AO, et al. Heterophilic antibodies interfering with radioimmunoassay. A false-positive pregnancy test. JAMA. 1982;248(19):2489–90.

    Article  CAS  PubMed  Google Scholar 

  70. Kelekci S, et al. Comparison of transvaginal sonography, saline infusion sonography, and office hysteroscopy in reproductive-aged women with or without abnormal uterine bleeding. Fertil Steril. 2005;84(3):682–6.

    Article  PubMed  Google Scholar 

  71. Soguktas S, et al. Comparison of saline infusion sonohysterography and hysteroscopy in diagnosis of premenopausal women with abnormal uterine bleeding. Eur J Obstet Gynecol Reprod Biol. 2012;161(1):66–70.

    Article  PubMed  Google Scholar 

  72. Doubilet PM. Diagnosis of abnormal uterine bleeding with imaging. Menopause. 2011;18(4):421–4.

    PubMed  Google Scholar 

  73. Lionaki S, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012;7(1):43–51.

    Article  CAS  PubMed  Google Scholar 

  74. Kaminski P, et al. Gynecological issues after organ transplantation. Neuro Endocrinol Lett. 2008;29(6):852–6.

    PubMed  Google Scholar 

  75. Kaunitz AM, et al. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2009;113(5):1104–16.

    Article  PubMed  Google Scholar 

  76. Kaunitz AM, Inki P. The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review. Drugs. 2012;72(2):193–215.

    Article  CAS  PubMed  Google Scholar 

  77. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86(2):714–5.

    CAS  PubMed  Google Scholar 

  78. Sundstrom A, et al. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the general practice Research database. BJOG. 2009;116(1):91–7.

    Article  CAS  PubMed  Google Scholar 

  79. Tengborn L, Blomback M, Berntorp E. Tranexamic acid – an old drug still going strong and making a revival. Thromb Res. 2015;135(2):231–42.

    Article  CAS  PubMed  Google Scholar 

  80. Weigert AL, Schafer AI. Uremic bleeding: pathogenesis and therapy. Am J Med Sci. 1998;316(2):94–104.

    CAS  PubMed  Google Scholar 

  81. Livio M, et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med. 1986;315(12):731–5.

    Article  CAS  PubMed  Google Scholar 

  82. Heistinger M, et al. Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF. Kidney Int. 1990;38(6):1181–6.

    Article  CAS  PubMed  Google Scholar 

  83. Vigano G, et al. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int. 1988;34(6):853–8.

    Article  CAS  PubMed  Google Scholar 

  84. Sloand JA, Schiff MJ. Beneficial effect of low-dose transdermal estrogen on bleeding time and clinical bleeding in uremia. Am J Kidney Dis. 1995;26(1):22–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Family Planning, Department of Obstetrics and Gynecology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA

    Elizabeth Schmidt

  2. Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA

    Sarah L. Pachtman

  3. Department of Obstetrics and Gynecology, University of California, Riverside, CA, USA

    Justin T. Diedrich

Authors
  1. Elizabeth Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah L. Pachtman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Justin T. Diedrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth Schmidt .

Editor information

Editors and Affiliations

  1. Division of Kidney Diseases and Hypertension, Department of Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, Great Neck, NY, USA

    Mala Sachdeva

  2. Division of Kidney Diseases and Hypertension, Department of Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, Great Neck, NY, USA

    Ilene Miller

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Schmidt, E., Pachtman, S.L., Diedrich, J.T. (2020). Contraception in Chronic Kidney Disease and Renal Transplantation. In: Sachdeva, M., Miller, I. (eds) Obstetric and Gynecologic Nephrology. Springer, Cham. https://doi.org/10.1007/978-3-030-25324-0_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25324-0_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25323-3

  • Online ISBN: 978-3-030-25324-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation